Patents Assigned to CORETHERAPIX, SLU
-
Patent number: 10016462Abstract: The present invention relates to the identification, isolation, expansion and characterization of a specific type of multipotent adult cardiac stem cell. These adult stem cells are characterized in that they naturally express a specific pattern of markers, which can be used to assist with their isolation and expansion. In particular, the cells express SOX17 and GATA4, but do not express Oct4, Nanog, c-kit and telomerase reverse transcriptase. These cells are able to differentiate into one or more of the following cell types: adipocytes, osteocytes, endothelial cells and/or smooth muscle cells. They also display an unprecedented capacity for immunoregulation as well as providing, activating and/or inducing repair of damaged cardiac tissue. These adult stem cells may be used as therapeutic agents including, without limitation, for the regeneration of tissue, particularly for regeneration of damaged cardiac tissue, such as myocardium.Type: GrantFiled: March 17, 2014Date of Patent: July 10, 2018Assignee: CORETHERAPIX SLUInventors: Luis Rodriguez-Borlado, Itziar Palacios, José Luis Abad, Belén Sánchez, Virginia Álvarez, Rosalba Rosado
-
Publication number: 20160030485Abstract: The present invention relates to the identification, isolation, expansion and characterization of a specific type of multipotent adult cardiac stem cell. These adult stem cells are characterised in that they naturally express a specific pattern of markers, which can be used to assist with their isolation and expansion. In particular, the cells express SOX17 and GATA4, but do not express Oct4, Nanog, c-kit and telomerase reverse transcriptase. These cells are able to differentiate into one or more of the following cell types: adipocytes, osteocytes, endothelial cells and/or smooth muscle cells. They also display an unprecedented capacity for immunoregulation as well as providing, activating and/or inducing repair of damaged cardiac tissue. These adult stem cells may be used as therapeutic agents including, without limitation, for the regeneration of tissue, particularly for regeneration of damaged cardiac tissue, such as myocardium.Type: ApplicationFiled: March 17, 2014Publication date: February 4, 2016Applicant: CORETHERAPIX SLUInventors: Luis RODRIGUEZ-BORLADO, Itziar PALACIOS, José Luis ABAD, Belén SÁNCHEZ, Virginia ÁLVAREZ, Rosalba ROSADO
-
Patent number: 8846099Abstract: The present invention relates to pharmaceutical formulations suitable for targeting particular tissue and/or organ(s) with a formulated active ingredient, for example when administered upstream of the target organ or tissue, and to use of the same in treatment, methods of treatment administering the same and methods of preparing the formulations. The pharmaceutical formulations of the invention are for parenteral administration to a target tissue and comprise particles containing an active ingredient, and a biodegradable excipient, wherein 90% or more of the particles have a diameter of between 10 and 20 microns and the formulation is substantially free of particles with a diameter greater than 50 microns and less than 5 microns, such that where the formulation is administered upstream of the target tissue the ability of the active to pass through the target tissue and pass into systemic circulation is restricted.Type: GrantFiled: April 30, 2013Date of Patent: September 30, 2014Assignee: Coretherapix, SLUInventor: Bernardo Nadal Ginard
-
Publication number: 20140271575Abstract: The present invention relates to the identification, isolation, expansion and characterization of a specific type of adult cardiac stem cell. These adult stem cells are characterised in that they naturally express a specific pattern of markers, which can be used to assist with their isolation and expansion. The cells of the invention display an unprecedented capacity for providing, activating and/or inducing repair of damaged cardiac tissue. These adult stem cells may be used as therapeutic agents including, without limitation, for the regeneration of tissue, particularly for regeneration of damaged cardiac tissue, such as myocardium.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: CORETHERAPIX SLUInventors: Luis RODRIGUEZ-BORLADO, Itziar PALACIOS, José Luis ABAD, Belén SÁNCHEZ, Virginia ÁLVAREZ, Rosalba ROSADO
-
Publication number: 20130315997Abstract: The present invention relates to pharmaceutical formulations suitable for targeting particular tissue and/or organ(s) with a formulated active ingredient, for example when administered upstream of the target organ or tissue, and to use of the same in treatment, methods of treatment administering the same and methods of preparing the formulations. The pharmaceutical formulations of the invention are for parenteral administration to a target tissue and comprise particles containing an active ingredient, and a biodegradable excipient, wherein 90% or more of the particles have a diameter of between 10 and 20 microns and the formulation is substantially free of particles with a diameter greater than 50 microns and less than 5 microns, such that where the formulation is administered upstream of the target tissue the ability of the active to pass through the target tissue and pass into systemic circulation is restricted.Type: ApplicationFiled: April 30, 2013Publication date: November 28, 2013Applicant: CORETHERAPIX, SLUInventor: CORETHERAPIX, SLU